Chapters

Transcript

Video

CAR T-Cells for Hematologic Malignancies and Beyond

In this data-drenched discussion, UCSF specialists review how CAR T-cells are being used in hematologic malignancies, including aggressive lymphoma and difficult-to-treat myeloma, as well as for solid tumors, and reveal what's on the horizon with regard to these products. They discuss current options, including response rates; factors that put patients at risk for failure; and how challenges – such as transience and toxicity – may be overcome. They also look at problems with patient access that inform decision-making, including the timing of referral.


Published

March 7, 2023

Created by

UCSF MedConnection

Related Presenters

Krishna Komanduri, MD

Krishna Komanduri, MD

Professor and Chief, Division of Hematology and Oncology

Professor and Chief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, UCSF

View Profile

Charalambos Andreadis, MD

Charalambos Andreadis, MD

Hematologist

Cancer therapy researcher and food aficionado

View Profile

Sandy Wong, MD

Sandy Wong, MD

Hematologist-oncologist

Wong is a member of the American Society of Hematology and American Society of Clinical Oncology.

View Profile

Julia Carnevale, MD

Julia Carnevale, MD

Assistant Professor, Medicine

School of Medicine

View Profile